Evidence map›Paper›PMID 42491044›Full record

ArticleAmerican journal of translational research2026

Effect of adalimumab treatment on lesions and inflammatory factors in patients with moderate-severe hidradenitis suppurativa.

Chenxu Niu, Shan An, Xiaoqian Hu, Zicheng Xiang, Wenfang Liu, Chenggong Cai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chenxu NiuSchool of Basic Medical Sciences, Capital Medical University Beijing 100069, China.
Shan AnSeong University in South Korea Daejeon 34606, South Korea.
Xiaoqian HuDepartment of Pharmacy, Xiantao Hospital of Traditional Chinese Medicine Xiantao 433000, Hebei, China.
Zicheng XiangDepartment of Dermatological, Cangzhou Central Hospital Cangzhou 061012, Hebei, China.
Wenfang LiuDepartment of Pharmacy, Dangyang Hospital of Traditional Chinese Medicine Dangyang 444100, Hubei, China.
Chenggong CaiDepartment of Health Management and Service, Medical Beauty Technology, Cangzhou Medical College Cangzhou 061001, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the efficacy and safety of adalimumab (ADA) in the treatment of hidradenitis suppurativa (HS).

methodsA retrospective analysis was conducted on the clinical data of 50 patients with HS. Patients were divided into ADA (n=30) and cyclosporine (CSA, n=20) groups. The Hidradenitis Suppurativa Clinical Response Criterion (HiSCR) and the International Hidradenitis Suppurativa Severity Score System (IHS4) were used to assess clinical efficacy. The Dermatology Life Quality Index (DLQI) was used to evaluate patients' quality of life, and peripheral blood inflammatory factor levels were measured. Safety was also assessed.

resultsAfter treatment, all scores in both groups decreased significantly (all

conclusionADA demonstrates good clinical efficacy and long-term safety in treating this population.

Indexed as

adalimumabadverse reactionsHidradenitis suppurativainflammatory factorsoutcome

Identifiers

PMID42491044
PMCPMC13376010

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.